N/A N=8 Women's Input on Sexual Health
Intravaginal Ring Use
Primary: USPE Scale Scores — 3.73; 3.63; 1.85; 2.02 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=473 ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
Covid19
Primary: Substudy Analysis Cohorts — 18; 21; 25; 21 Participants
N/A N=30 Sugammadex and Quantitative Monitoring in "Fast-Track Anesthesia" During Liver Transplantation
Liver Transplant Surgery
Primary: Incidence of Postoperative Residual Weakness in the Recovery Room — 2; 0 Participants
N/A N=31,432 Data-driven Identification for Substance Misuse
Substance Use · Substance Abuse · Substance-Related Disorders
Primary: Proportion of Patients That Had a Universal Screen Positive and Received SBIRT (Screening, Brief Intervention, or Referral to Treatment) — 1189; 1144 Participants — p=0.20
N/A N=200 Using Social Media to Decrease Healthcare Utilization for Pediatric Asthma
Asthma in Children
Primary: Total Number of Treatment Days in a Medical Setting (Hospital, Emergency Department (ED), Clinic) — 1.97; 2.67 days
Phase 2 N=89 A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Melanoma · Carcinoma, Hepatocellular · Colorectal Neoplasms
Primary: Phase 1b Part: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0 Participants
N/A N=234 LifeBio Memory Digital Reminiscence Platform
Dementia · Cognitive Impairment
Primary: Change in Center for Epidemiological Studies Depression Scale (CES-D) From Baseline — 7.04; 6.09 score on a scale — p=0.020
Phase 3 N=1,029 A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
Neovascular Age-related Macular Degeneration
Primary: Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale — 188; 207; 16; 114…
N/A N=18 Dietary Salt in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change in Tissue Sodium — 17.1; 16.7 mmol/L — p=0.55
Phase 2 N=30 Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses
Actinic Keratosis
Primary: Treatment Efficacy Based on Participant AK Lesion Clearance — 59; 34; 43; 76 percentage of AK lesions
Phase 2 N=125 Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 17; 17; 24; 20 Participants
Phase 3 N=17 Efficacy of SLN Block for Chronic Cough
Cough · Superior Laryngeal Nerve Block · Neurogenic Cough
Primary: Change in Cough Severity — 13.15; 9.54 LCQ scores (baseline to 3 months)
N/A N=2,244 Old SCHOOL Hip-Hop: Improve Alzheimer's Disease Knowledge
Dementia
Primary: OSHH Program Effectiveness of Educating Parents at 1-week and 3-months After the Intervention Using ASK-AD 7 — 5.14; 5.28; 5.41; 5.62 score on a scale
N/A N=376 DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation
Persistent Atrial Fibrillation · Atrial Fibrillation
Primary: Primary Safety Events — 16 participants
Phase 1 N=40 Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults
Nipah Virus Infection
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 1; 1; 0; 4 Participants